About Us

Medibiofarma is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry.

We aim to generate innovative and high-quality research programs based on the modulation of clinically validated therapeutic targets.

Mission

To propel the development of disease-modifying therapies for patients with serious diseases where no treatment currently exists.

To design tailored small molecules for well-validated biological targets in new disease areas.

To provide extensively de-risked clinical assets for licensing by completing proof-of-concept trials in patients.

At Medibiofarma, we are:

  • The Drug Discovery Process
  • Virtual Drug Design
  • Medicinal Chemistry
  • Intellectual Property
  • Project Management
  • Clinical trials
  • Business Development
  • Raising Funds

All activities are carried out internally or through partnerships with contract research organizations, research centres and universities.

Leading scientists

Rodolfo Rodríguez Iglesias

Co-Founder, CEO & IP director

Rodolfo Rodríguez Iglesias is Chemical Engineer, Master in Science in Biotechnological Processes and Patent Technician.

He has 15 years of experience in industrial property and 8 years as a specialist in vaccine production.

With knowledge in the protection of inventions and strategies for the registration of intellectual property, drafting of patents, patent research, patentability studies, infringement studies, freedom to operate, procedures for processing and examining national and European patents, and international applications of patents, and in the biotechnological sector in fermentation, molecular biology, basic immunology, etc.

He is Co-founder and IP director of Medibiofarma.

Richard Roberts, PhD

Chief Scientific Officer

Richard holds a degree in Natural Sciences and a PhD in Organic Chemistry from the University of Cambridge, followed by a three-year post-doc at Imperial College, London.

He has 20 years’ experience in the field of medicinal chemistry and drug discovery. After a spell as Team Leader at Syngenta, UK, he moved to Almirall in Barcelona in 2002 as a Senior Medicinal Chemist. From 2008 he was Program Leader, discovering potent molecules related to asthma, cough and itch. He was also involved in a range of other activities, from open innovation and compound logistics to managing major collaborations.

Since 2016 he has been in the biotech sector, first as Director of Drug Discovery at Minoryx, a clinical-stage company focused on rare genetic disorders. He was then Director of Medicinal Chemistry at the Kærtor Foundation, a pioneer incubator for early drug discovery in collaboration with industry.

He joined Medibiofarma as Chief Scientific Officer in 2020

Horacio Moreno, PhD

Director of Business Development

Horacio holds a degree in Biochemistry, and a PhD in Biochemistry and Molecular Biology from the University of Barcelona, with a postgraduate stage at the University of Heidelberg, Germany.

He started his career in Business Development and Licensing at Almirall in 2002, and since then has held different positions of increasing responsibility in this area at Almirall, Gebro Pharma and Menarini, where he was regional head for BD for Spain and Latin America. He has also collaborated with several local biotech companies and research centres, including AVX Pharma, which was sold to Aerie Pharmaceuticals in a transaction closed in 2019.

He combines this professional activity in Business Development with teaching at the University for Biotechnology students (IQS, Institut Químic de Sarriá, URL).

Horacio joined Medibiofarma as Director of Business Development in October 2021.

Luc Marti, PhD, MBM

Director of Clinical Development

Luc holds a degree in Biochemistry, a degree in Physiology, a PhD in Pharmacology from Université Paul Sabatier, Toulouse, and a Master in Biotechnology Management from the IE business school.

He has 25 years’ experience in basic and applied pharmacology, of which 18 years have been dedicated to drug development. He cofounded Genmedica Therapeutics developing an antidiabetic compound up to phase 2a. In 2013 he became COO and then senior VP R&D operations at Artax Biopharma where he supervised the development of an autoimmune modulator up to phase 1b. In 2016, as COO of Cebiotex, he managed the development, including preclinic, GMP and phase 1 of an implantable drug delivery system for patients with cancer.

He joined Medibiofarma as Director of Clinical Development in 2023

Andrea Gonella, PhD

Director of CMC

Andrea holds a Bachelor’s and Master’s degree in Industrial Biotechnology from the University of Milano-Bicocca, and a PhD in Drug Research and Development (Marie Curie Fellowship) from the University of Santiago de Compostela.

Before completing his PhD, Andrea began his career as a scientist at the pharmaceutical company Medincell S.A. (France), where he worked for five years developing long‑acting injectable formulations for protein therapeutics. During this time, he led several projects and progressively assumed greater responsibilities.

Andrea then returned to Spain to join Recordati (Spain) as Pharmaceutical Technology Manager, a role he held from 2023 to 2025. At Recordati, he led multiple cross‑functional projects involving Medical Affairs, Industrial Operations, Quality, Marketing, and other departments, and he was responsible for R&D as well as part of the CMC activities.

Driven by an innate curiosity, Andrea completed in 2026 an Executive Program in Artificial Intelligence applied to the biopharmaceutical industry.

He joined Medibiofarma as Director of CMC in 2025

Victoria Revilla, PhD

Chief Business Officer

Victoria Revilla holds a PhD in Biology and CNS Pharmacology from the University of León and an MBA from Universitat Pompeu Fabra and completed postdoctoral research at the MRC Laboratory of Molecular Biology in Cambridge.

She has more than 25 years of international experience in the pharmaceutical and biotechnology industries, including senior roles at Almirall and Galderma, spanning drug development, new product planning, business development, licensing, market access and commercial strategy..

She joined Medibiofarma as Chief Business Officer in January 2026, combining scientific expertise with business and development strategy to advance innovative medicines from research towards clinical development and partnering..

She joined Medibiofarma as Chief Business Officer in 2026

Natalia Pérez, PhD

Director of Biology

Victoria Revilla holds a PhD in Biology and CNS Pharmacology from the University of León and an MBA from Universitat Pompeu Fabra and completed postdoctoral research at the MRC Laboratory of Molecular Biology in Cambridge.

She has more than 25 years of international experience in the pharmaceutical and biotechnology industries, including senior roles at Almirall and Galderma, spanning drug development, new product planning, business development, licensing, market access and commercial strategy..

She joined Medibiofarma as Chief Business Officer in January 2026, combining scientific expertise with business and development strategy to advance innovative medicines from research towards clinical development and partnering..

She joined Medibiofarma as Director of Biology in 2026